Joan T. Garrett

2.8k total citations · 1 hit paper
30 papers, 2.0k citations indexed

About

Joan T. Garrett is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Joan T. Garrett has authored 30 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 18 papers in Molecular Biology and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Joan T. Garrett's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Joan T. Garrett is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Joan T. Garrett collaborates with scholars based in United States, Italy and Australia. Joan T. Garrett's co-authors include Carlos L. Arteaga, Rosalin Mishra, Samar Alanazi, Hima Patel, Brent N. Rexer, Todd W. Miller, Long Yuan, Rebecca S. Cook, Anindita Chakrabarty and Violeta Sánchez and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Joan T. Garrett

29 papers receiving 2.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

2021 194 citations Rosalin Mishra, Hima Patel et al. International Journal of Molecular Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joan T. Garrett United States	19	1.2k	1.1k	599	392	229	30	2.0k
Thomas Holbro Switzerland	11	1.3k 1.1×	1.3k 1.1×	672 1.1×	300 0.8×	209 0.9×	17	2.3k
Edward Rosfjord United States	19	938 0.8×	1.0k 0.9×	358 0.6×	383 1.0×	271 1.2×	39	1.9k
Keng‐Hsueh Lan Taiwan	13	1.5k 1.3×	1.5k 1.4×	760 1.3×	381 1.0×	325 1.4×	21	2.5k
Mathias Schmidt Germany	25	1.3k 1.1×	1.1k 0.9×	316 0.5×	274 0.7×	278 1.2×	59	2.2k
Cammie Rinehart United States	15	1.7k 1.4×	1.7k 1.5×	719 1.2×	567 1.4×	327 1.4×	19	2.8k
Xuewu Zhang China	11	1.1k 0.9×	879 0.8×	485 0.8×	434 1.1×	94 0.4×	29	1.8k
T. Khanh United States	26	1.6k 1.4×	991 0.9×	422 0.7×	462 1.2×	473 2.1×	57	2.5k
Neil A. O’Brien United States	23	821 0.7×	1.0k 0.9×	375 0.6×	455 1.2×	265 1.2×	55	1.6k
Cornelia Quadt Switzerland	25	1.4k 1.2×	756 0.7×	234 0.4×	591 1.5×	273 1.2×	53	2.2k
Jordi Codony‐Servat Spain	22	1.2k 1.1×	1.5k 1.3×	616 1.0×	665 1.7×	553 2.4×	56	2.5k

Countries citing papers authored by Joan T. Garrett

Since Specialization

Citations

This map shows the geographic impact of Joan T. Garrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan T. Garrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan T. Garrett more than expected).

Fields of papers citing papers by Joan T. Garrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan T. Garrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan T. Garrett. The network helps show where Joan T. Garrett may publish in the future.

Co-authorship network of co-authors of Joan T. Garrett

This figure shows the co-authorship network connecting the top 25 collaborators of Joan T. Garrett. A scholar is included among the top collaborators of Joan T. Garrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan T. Garrett. Joan T. Garrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garrett, Joan T., et al.. (2025). Emerging importance of HER3 in tumorigenesis and cancer therapy. Nature Reviews Clinical Oncology. 22(5). 348–370. 7 indexed citations

Mishra, Rosalin, et al.. (2024). HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer. Molecular Carcinogenesis. 63(8). 1528–1541. 1 indexed citations

Patel, Hima, et al.. (2022). HER3 Alterations in Cancer and Potential Clinical Implications. Cancers. 14(24). 6174–6174. 13 indexed citations

Patel, Hima, et al.. (2021). IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers. 13(22). 5863–5863. 19 indexed citations

Mishra, Rosalin, et al.. (2021). PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. International Journal of Molecular Sciences. 22(7). 3464–3464. 194 indexed citations breakdown →

Patel, Hima, et al.. (2020). Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers. 12(2). 482–482. 132 indexed citations

Mishra, Rosalin, Hima Patel, Long Yuan, & Joan T. Garrett. (2018). Role of Reactive Oxygen Species and Targeted Therapy in Metastatic Melanoma. 4(1). 101–130. 3 indexed citations

Yuan, Long, Rosalin Mishra, Hima Patel, et al.. (2018). Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma. Journal of Cancer. 9(24). 4665–4676. 23 indexed citations

Mishra, Rosalin, Hima Patel, Samar Alanazi, Long Yuan, & Joan T. Garrett. (2018). HER3 signaling and targeted therapy in cancer. Oncology Reviews. 12(1). 355–355. 140 indexed citations

10.

Mishra, Rosalin, Ariella B. Hanker, & Joan T. Garrett. (2017). Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 8(69). 114371–114392. 89 indexed citations

11.

Garrett, Joan T., Cammie R. Sutton, Richard Kurupi, et al.. (2013). Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers. Cancer Research. 73(19). 6013–6023. 72 indexed citations

12.

Garrett, Joan T., Cammie R. Sutton, Carl Uli Bialucha, et al.. (2013). Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .. Cancer Research. 73(8_Supplement). 5461–5461. 1 indexed citations

13.

Garrett, Joan T., Cammie R. Sutton, M. Gabriela Kuba, Rebecca S. Cook, & Carlos L. Arteaga. (2012). Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function. Clinical Cancer Research. 19(3). 610–619. 81 indexed citations

14.

Garrett, Joan T., Cammie R. Sutton, Rebecca S. Cook, & Carlos L. Arteaga. (2012). Abstract 3867: Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function completely: Clinical implications. Cancer Research. 72(8_Supplement). 3867–3867. 1 indexed citations

15.

Cook, Rebecca S., Joan T. Garrett, Violeta Sánchez, et al.. (2011). ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis. Cancer Research. 71(11). 3941–3951. 64 indexed citations

16.

Garrett, Joan T., Maria G. Olivares, Cammie Rinehart, et al.. (2011). Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences. 108(12). 5021–5026. 359 indexed citations

17.

Miller, Todd W., Brent N. Rexer, Joan T. Garrett, & Carlos L. Arteaga. (2011). Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Research. 13(6). 224–224. 359 indexed citations

18.

Garrett, Joan T. & Carlos L. Arteaga. (2011). Resistance to HER2-directed antibodies and tyrosine kinase inhibitors. Cancer Biology & Therapy. 11(9). 793–800. 145 indexed citations

19.

Garrett, Joan T., Sharad Rawale, Gary Phillips, et al.. (2007). Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo. The Journal of Immunology. 179(1). 472–482. 45 indexed citations

20.

Garrett, Joan T., Sharad Rawale, Gary Phillips, et al.. (2007). Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu. The Journal of Immunology. 178(11). 7120–7131. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact